Arcus Biosciences

Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.